BR112016002317A8 - Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos - Google Patents

Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos

Info

Publication number
BR112016002317A8
BR112016002317A8 BR112016002317A BR112016002317A BR112016002317A8 BR 112016002317 A8 BR112016002317 A8 BR 112016002317A8 BR 112016002317 A BR112016002317 A BR 112016002317A BR 112016002317 A BR112016002317 A BR 112016002317A BR 112016002317 A8 BR112016002317 A8 BR 112016002317A8
Authority
BR
Brazil
Prior art keywords
benralizumab
antigen
binding fragment
asthmatics
expiratory volume
Prior art date
Application number
BR112016002317A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016002317A2 (pt
Inventor
Ward Christine
Roskos Lorin
Wang Bing
Raible Donald
Original Assignee
Medimmune Llc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Astrazeneca Ab filed Critical Medimmune Llc
Publication of BR112016002317A2 publication Critical patent/BR112016002317A2/pt
Publication of BR112016002317A8 publication Critical patent/BR112016002317A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
BR112016002317A 2013-08-12 2014-08-07 Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos BR112016002317A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (2)

Publication Number Publication Date
BR112016002317A2 BR112016002317A2 (pt) 2017-12-12
BR112016002317A8 true BR112016002317A8 (pt) 2018-06-12

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002317A BR112016002317A8 (pt) 2013-08-12 2014-08-07 Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos

Country Status (26)

Country Link
US (1) US9441046B2 (https=)
EP (5) EP3033104B1 (https=)
JP (4) JP6746496B2 (https=)
KR (1) KR102337599B1 (https=)
CN (2) CN105451769A (https=)
AU (2) AU2014306959B2 (https=)
BR (1) BR112016002317A8 (https=)
CA (1) CA2917603C (https=)
CY (2) CY1122033T1 (https=)
DK (2) DK3033104T3 (https=)
ES (2) ES2866426T3 (https=)
HK (1) HK1222559A1 (https=)
HR (2) HRP20190920T1 (https=)
HU (2) HUE043497T2 (https=)
LT (2) LT3520811T (https=)
ME (1) ME03403B (https=)
MX (2) MX381102B (https=)
PL (2) PL3520811T3 (https=)
PT (2) PT3520811T (https=)
RS (2) RS58711B1 (https=)
RU (1) RU2703568C2 (https=)
SG (1) SG11201600483QA (https=)
SI (2) SI3033104T1 (https=)
SM (2) SMT201900311T1 (https=)
TR (1) TR201907907T4 (https=)
WO (1) WO2015023507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
SI3060229T1 (sl) 2013-10-24 2021-11-30 Astrazeneca Ab Stabilne vodne formulacije protiteles
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法

Also Published As

Publication number Publication date
SMT202100152T1 (it) 2021-05-07
RU2016108809A (ru) 2017-09-18
WO2015023507A3 (en) 2015-04-09
US9441046B2 (en) 2016-09-13
EP4636400A2 (en) 2025-10-22
CN111588849A (zh) 2020-08-28
CY1122033T1 (el) 2020-10-14
PL3520811T3 (pl) 2021-08-02
CY1124399T1 (el) 2022-07-22
LT3520811T (lt) 2021-03-25
HK1225300A1 (en) 2017-09-08
CA2917603A1 (en) 2015-02-19
RS58711B1 (sr) 2019-06-28
KR102337599B1 (ko) 2021-12-10
EP4579236A2 (en) 2025-07-02
RU2016108809A3 (https=) 2018-06-18
SG11201600483QA (en) 2016-02-26
JP2020125304A (ja) 2020-08-20
HK1222559A1 (zh) 2017-07-07
TR201907907T4 (tr) 2019-06-21
HRP20190920T1 (hr) 2019-07-12
SMT201900311T1 (it) 2019-07-11
EP3875487A1 (en) 2021-09-08
JP2022120010A (ja) 2022-08-17
AU2014306959A1 (en) 2016-02-04
HUE043497T2 (hu) 2019-08-28
DK3033104T3 (da) 2019-06-17
RS61565B1 (sr) 2021-04-29
EP3033104A2 (en) 2016-06-22
CA2917603C (en) 2023-05-16
HRP20210406T1 (hr) 2021-04-30
EP3033104B1 (en) 2019-04-03
ES2866426T3 (es) 2021-10-19
JP6746496B2 (ja) 2020-08-26
JP2024129140A (ja) 2024-09-26
EP4636400A3 (en) 2025-12-24
MX2021003826A (es) 2021-05-27
SI3520811T1 (sl) 2021-04-30
SI3033104T1 (sl) 2019-06-28
DK3520811T3 (da) 2021-03-22
EP3033104A4 (en) 2017-03-22
ES2733602T3 (es) 2019-12-02
WO2015023507A2 (en) 2015-02-19
EP3520811A1 (en) 2019-08-07
EP4579236A3 (en) 2025-09-17
LT3033104T (lt) 2019-06-25
MX381102B (es) 2025-03-12
JP2016527325A (ja) 2016-09-08
WO2015023507A8 (en) 2015-09-24
PT3033104T (pt) 2019-06-27
PT3520811T (pt) 2021-03-15
AU2014306959B2 (en) 2019-11-21
RU2703568C2 (ru) 2019-10-21
HUE053627T2 (hu) 2021-07-28
KR20160043049A (ko) 2016-04-20
CN105451769A (zh) 2016-03-30
MX2016001384A (es) 2016-08-03
AU2020201277A1 (en) 2020-03-12
BR112016002317A2 (pt) 2017-12-12
US20150044203A1 (en) 2015-02-12
EP3520811B1 (en) 2020-12-30
PL3033104T3 (pl) 2019-09-30
ME03403B (me) 2020-01-20

Similar Documents

Publication Publication Date Title
BR112016002317A8 (pt) Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BR112014030406A8 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MX2016002166A (es) Anticuerpos.
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
BR112016008082A2 (pt) métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
BR112016002462A8 (pt) Métodos para melhorar os sintomas da asma usando benralizumabe
BR112018015090A2 (pt) anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112015009310A2 (pt) composição em pó, dose unitária da composição e uso não médico da composição ou da dose unitária.
CL2015001481A1 (es) Uso de extracto bacopa monnieri
BR112017001038A2 (pt) vitamina b2 e seu uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.